what is bronchitis

Info about bronchitis coughing => bronchitis cures => Topic started by: glennaguilar on June 14, 2016, 11:59:37 am


Title: Laryngo Tracheo Bronchitis: Intense Home Care in Acute
Post by: glennaguilar on June 14, 2016, 11:59:37 am
Laryngo Tracheo Bronchitis - Intense Home Care in Acute  Bronchitis
Acute bronchitis the most important is to stay calm and relax. Camomille tea and chicken soup are said to be the best remedies.         Because sometimes bronchitis is mistaken with a simple flu patients try to treat it on their own. Emergen -C style vitamins, Robitussin may help you to cough and expectorate and have a good sleep during the night. You should stay in door and in warm places (in bed) and let your organism to take care of it. Hot baths and plenty of fluids are of great help, when you sleep maintain a half sitting up position so as to cough less.

Eating honey is also heplfull because it may soothe the throat. For acute bronchitis you do not need antibiotics so the infection will disappear in one week, if you have fever you may take aspirin, do not smoke. For a secondary bacterial infection antibiotics are prescribed and maybe an inhaler and an expectorant. Theraflu  and tea with lemon and honey, hot toddies with bourbon  are helpfully. For some people with bronchitis hot baths instead of steam are better. An idle brain, is a devil's workshop they say. Using this ideology in mind, we ventured to eitrige bronchitis (http://feliciad.forumo.de/bronchitis-lung-f8/eitrige-bronchitis-t25.html) Dry, so that something productive would be achieved of our minds.

Quote
You have trouble breathing in the Emergency Room you may be given an albuterol breathing treatment, an inhaler, and some prednasone. Bronchitis may complicate with pneumonia and that is quite severe, especially in children which are not supervized by parents and they do not treat well or at whole their bronchitis. That's why important to have rest and warm.       Sometimes only the rest and the home care won't help so try to visit your doctor and  buy your drugs, even more important is to take them. If you notice that your health is not improved in one week than you may suspect a complication, the most probable one is pneumonia. A cough may continue for several more weeks, the progression of chronic bronchitis, on the other hand, may be slowed, but an initial improvement in symptoms may be achieved. Writing something about Chronic Bronchitis seemed to be something illogical in the beginning. However, with the progress of matter, it seemed logical. Matter just started pouring in, to give you this finished product.

For those with chronic disease and very young children preventive measures have a high importance so immunizations are highly recommended. If you are unsure about what type of medications are in over-the-counter cough syrups  you should ask the pharmacist for an explanation.      If you have these symptoms you are likely to develop acute bronchitis: dry, hacking unproductive cough that may change to a loose cough with increased mucus,  runny nose, sore throat, back and other muscle pains, chills and low grade fever, headache and general malaise (feeling unwell). Wheezing after coughing is common.

The fluoroquinolones are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they are really modified quinolones, a class of antibiotics, whose accidental discovery occurred in the early 1960.

Side Effects
The fluoroquinolones as a class are generally well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they can have serious adverse effects. ;)

The fluoroquinolones are a family of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of the group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The first fluoroquinolones were widely used because they were the only orally administered agents available for the treatment of serious infections caused by gram-negative organisms, including Pseudomonas species. You may say that we have included exquisite information here on Bronchitis. This is with the intention of producing a unique article on Bronchitis.

Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin are the most widely used second-generation quinolones because of their availability in oral and intravenous formulations and their broad set of FDA-labeled indications.

All of the fluoroquinolones are effective in treating urinary tract infections caused by susceptible organisms. They are the first-line treatment of acute uncomplicated cystitis in patients who cannot tolerate sulfonamides or TMP, who live in geographic areas with known resistance > 10% to 20% to TMP-SMX, or who have risk factors for such resistance. This is the counterpart to our previous paragraph on Bronchitis. Please read that paragraph to get a better understanding to this paragraph.

Fourth Generation
The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan). It was with great optimism that we started out on writing this composition on Chronic Bronchitis. Please don't let us lose this optimism.

The newer fluoroquinolones have a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones have an important role in the treatment of community-acquired pneumonia and intra-abdominal infections.

Fluoroquinolones disadvantages:    Tendonitis or tendon rupture  Multiple drug interactions Not used in children Newer quinolones produce additional toxicities to the heart that were not found with the older agents

Third Generation
The third-generation fluoroquinolones are separated into a third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. Although the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species. :o.

Fluoroquinolones are approved for use only in people older than 18. They can affect the growth of bones, teeth, and cartilage in a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy is not recommended unless the benefits justify the potential risks to the fetus. These agents are also excreted in breast milk and should be avoided during breast-feeding if at all possible.

Classification of Fluoroquinolones  As a group, the fluoroquinolones have excellent in vitro activity against a wide range of both gram-positive and gram-negative bacteria. The newest fluoroquinolones have enhanced activity against gram-positive bacteria with only a minimal decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae.

Gastrointestinal Effects
The most common adverse events experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients.  CNS effects. Headache, dizziness, and drowsiness have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. With the older non-fluorinated quinolones neurotoxic symptoms such as dizziness occurred in about 50% of the patients.  Phototoxicity. Exposure to ultraviolet A rays from direct or indirect sunlight should be avoided during treatment and several days (5 days with sparfloxacin) after the use of the drug. The degree of phototoxic potential of fluoroquinolones is as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Concern about the development of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.  Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have been reported as long as nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use has been associated with rare liver damage, which prompted the withdrawal of the oral preparations from the U.S. market. However, the IV preparation is still available for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities to the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin may have the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur only occasionally during quinolone therapy and are generally mild to moderate in severity, and usually resolve after treatment is stopped. Patience was exercised in this article on Bronchitis. Without patience, it would not have been possible to write extensively on Bronchitis.

Second Generation
The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. Compared with first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections. We have actually followed a certain pattern while writing on Bronchitis. We have used simple words and sentences to facilitate easy understanding for the reader.

Fluoroquinolones Advantages:
Ease of administration Daily or twice daily dosing  Excellent oral absorption Excellent tissue penetration  Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety Penetration into the world of Chronic Bronchitis proved to be our idea in this article. Read the article and see if we have succeeded in this or not!

First Generation
The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they are more susceptible to the development of bacterial resistance.